JP2012508749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508749A5 JP2012508749A5 JP2011536438A JP2011536438A JP2012508749A5 JP 2012508749 A5 JP2012508749 A5 JP 2012508749A5 JP 2011536438 A JP2011536438 A JP 2011536438A JP 2011536438 A JP2011536438 A JP 2011536438A JP 2012508749 A5 JP2012508749 A5 JP 2012508749A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- bendamustine
- bortezomib
- multiple myeloma
- patent document
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11428408P | 2008-11-13 | 2008-11-13 | |
| US61/114,284 | 2008-11-13 | ||
| PCT/US2009/064009 WO2010056733A1 (en) | 2008-11-13 | 2009-11-11 | Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508749A JP2012508749A (ja) | 2012-04-12 |
| JP2012508749A5 true JP2012508749A5 (https=) | 2012-12-27 |
Family
ID=42170295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536438A Pending JP2012508749A (ja) | 2008-11-13 | 2009-11-11 | 多発性骨髄腫治療のためのベンダムスチン、ドキソルビシンおよびボルテゾミブの併用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110217258A1 (https=) |
| EP (1) | EP2350665A4 (https=) |
| JP (1) | JP2012508749A (https=) |
| CA (1) | CA2741276A1 (https=) |
| MX (1) | MX2011005054A (https=) |
| WO (1) | WO2010056733A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918968B2 (en) | 2013-01-03 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | Rapamycin analogs targeting proteasome function in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7815921B2 (en) * | 2002-03-22 | 2010-10-19 | Ludwid Maximilians Universitat | Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy |
| ES2421516T3 (es) * | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
| WO2006069073A2 (en) * | 2004-12-20 | 2006-06-29 | The General Hospital Corporation | Use of angiopoietins in anti-tumor therapy |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
-
2009
- 2009-11-11 WO PCT/US2009/064009 patent/WO2010056733A1/en not_active Ceased
- 2009-11-11 MX MX2011005054A patent/MX2011005054A/es not_active Application Discontinuation
- 2009-11-11 CA CA2741276A patent/CA2741276A1/en not_active Abandoned
- 2009-11-11 JP JP2011536438A patent/JP2012508749A/ja active Pending
- 2009-11-11 EP EP09826660A patent/EP2350665A4/en not_active Withdrawn
-
2011
- 2011-04-28 US US13/096,300 patent/US20110217258A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paoluzzi et al. | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas | |
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| MX2021011500A (es) | Anticuerpos multiespecificos egfr x cd28. | |
| JP2015534577A5 (https=) | ||
| Dings et al. | Enhancement of T-cell–mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer | |
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| JP2019510832A5 (https=) | ||
| JP2015534580A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| JP2018516969A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2012509259A5 (https=) | ||
| JP2013533858A5 (https=) | ||
| MX2010005099A (es) | Usos de anticuerpos anti-cd40. | |
| JP2013507415A5 (https=) | ||
| JP2016502504A5 (https=) | ||
| UA115517C2 (uk) | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b | |
| AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
| JP2013538790A5 (https=) | ||
| JP2015503596A5 (https=) | ||
| JP2018516936A5 (https=) | ||
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| JP2013544892A5 (https=) | ||
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака |